Throughout the COVID-19 pandemic, variants of concern (VOC) have driven new waves of infection and negatively affected the efficacy of existing therapeutics. As such, identifying new antibodies capable of providing durable protection either across multiple variants or specifically for novel ones is paramount. Patient vaccination induces the in vivo production of a broad and varied range of antibodies, and is the predominant source of therapeutic antibodies. A recent study shows that vaccination against SARS-CoV-2 can yield antibodies with efficacy against other or yet-unknown viral variants.

Download this research summary from PhenomeX to learn more about how researchers found antibodies with efficacy against Omicron lineages in a patient double-vaccinated with the Moderna mRNA-1273 vaccine six months prior to the emergence of the Omicron variants.

Sponsored by